The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis and 45 with Crohn disease, at 14 centers in Italy.
Since CT-P13 (Inflectra, Remsima), an infliximab biosimilar referencing Remicade, was authorized for use in Europe, numerous studies have investigated the safety and efficacy of the biosimilar in the inflammatory bowel disease (IBD) population. Now, a study of a large outpatient cohort with IBD in Italian primary centers has added to the growing body of data on the long-term efficacy and safety of the biosimilar.
The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis (UC) and 45 with Crohn disease (CD), at 14 centers. The patients initiated the biosimilar between 2015 and 2017. Most of the patients were naïve to anti—tumor necrosis factor (anti-TNF) agents (26% in the UC group and 28.9% in the CD group had previous anti-TNF exposure, and most were given the biosimilar after a loss of response to another anti-TNF).
Patients received CT-P13 at 5 mg/kg via infusion at weeks 0, 2, and 6, and then every 8 weeks thereafter. Dose escalation was used when necessary to maintain remission.
During a median follow-up of 24 (range, 6-24) months, remission, as assessed by Mayo score in the UC group and by the Harvey-Bradshaw Index in the CD group, was achieved by 57.3% of patients in the UC group and 75.6% of patients in the CD group.
Among patients who had previous anti-TNF exposure, 48.0% of patients with UC and 61.5% of patients with CD achieved remission.
Mucosal healing was observed in 75% of the UC group and 84.2% of the CD group, and 96.9% and 97.8% of patients in the respective groups were able to reduce their dose of steroids. In total, 2.1% and 6.7% of patients in each group went on to have IBD-related surgery during the follow-up period.
Only 1 adverse event was reported: A skin reaction occurred in a patient at the time of infusion, leading to an interruption of treatment.
According to the authors, this first Italian study to include a follow-up of 24 months shows the biosimilar’s efficacy and safety in the primary, outpatient IBD setting. Longer-term studies, they add, will be needed to assess switching from the reference to the biosimilar.
Reference
Tursi A, Mocci G, Faggiani R, et al. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life, multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol. 2019;21(4):392-399. doi: 10.20524/aog.2019.0377.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.